P-wave duration and dispersion in patients with metabolic syndrome

Metabolic syndrome (MS) has been reported to be associated with an increased risk of atrial fibrillation (AF). The aim of this study was to investigate P-wave dispersion (PWD) in patients with MS.

The study population included 66 patients with MS (21 men, 45 women; mean age, 49.7 +/- 9.1 years) and 63 control subjects without MS (26 men, 37 women; mean age, 47.0 +/- 10.6 years). The diagnosis of MS was based on the National Cholesterol Education Program Adult Treatment Panel III criteria. A 12-lead electrocardiogram was recorded for each subject. The difference between maximum and minimum P-wave duration was calculated and defined as PWD. An echocardiographic examination was also performed for each subject.

Maximum P-wave duration and PWD were found to be significantly higher in patients with MS compared with the control subjects (Maximum P-wave duration: 113.5 +/- 9.7 ms vs 101.0 +/- 8.1 ms, PWD: 37.8 +/- 7.6 vs 23.3 +/- 5.9, respectively, P < 0.001 for both). However, there was no statistically significant difference between two groups regarding minimum P-wave duration (75.6 +/- 6.9 ms vs 77.6 +/- 7.8 ms, respectively, P = 0.18). In addition, PWD was positively correlated with age, body mass index, waist circumference, systolic and diastolic blood pressure, triglyceride level, deceleration time, isovolumetric relaxation time and negatively correlated with high-density lipoprotein cholesterol level and early-to-late diastolic velocity ratio.

We have shown that patients with MS have higher PWD, indicating increased risk for AF, compared to the control subjects without MS.